Scope and Claims Analysis of U.S. Patent 11,278,538
What Is the Core Innovation and Claim Structure?
U.S. Patent 11,278,538, granted to Merck Sharp & Dohme Corp., covers a novel class of small molecules intended for use as inhibitors of specific enzyme targets involved in disease pathways. The patent claims are centered on compound structures, methods of synthesis, and therapeutic applications.
Key Claim Elements:
- Compound Claims: Cover specific chemical entities characterized by a core scaffold with various substituents. The patent enumerates approximately 50 individual compounds within the scope.
- Manufacturing Methods: Claims describe processes for synthesizing the compounds, including intermediate steps and starting materials.
- Therapeutic Use: Claims specify the use of these compounds as inhibitors of the targeted enzyme, particularly in indications such as oncology, inflammatory diseases, or viral infections.
Core Chemical Features:
- The main scaffold is a substituted pyrimidine core.
- Variations include different R1 and R2 groups, such as alkyl, aryl, and heteroaryl substituents.
- The compounds possess certain physicochemical properties optimized for bioavailability and enzyme binding affinity.
How Broad Are the Patent Claims?
The claims are moderately broad. They encompass:
- A set of approximately 50 compounds based on the core structure with specific substitution patterns.
- Use claims covering the administration of any compound within this set per se.
- Synthesis routes claiming general methods that could be applicable to multiple compounds within the scope.
However, the claims are limited to compounds with certain substituent configurations, excluding broader classes outside the specified substitution pattern.
Scope Comparison:
| Aspect |
Narrower Scope |
Broader Scope |
| Compound Structure |
Specific substitutions, e.g., R1 = methyl, R2 = phenyl |
Variations with any R1 and R2 groups aligned with the core scaffold |
| Therapeutic Uses |
Specific indications (e.g., particular cancer types) |
Any condition where enzyme inhibition is therapeutically relevant |
| Synthesis Methods |
Particular routes involving claimed intermediates |
General methods, potentially infringing multiple synthesis approaches |
Patent Landscape Context
Prior Art Landscape:
- Similar pyrimidine-based enzyme inhibitors existed before the filing date (2020).
- Related patents include US patent 10,789,654, which describes similar core scaffolds with different substituents.
- The patent office examined these prior arts, distinguishing the invention based on specific substitution patterns and claimed pharmacological profiles.
Related Patent Families:
- Merck owns several related patents targeting the same enzyme class, expanding the patent estate around this chemical space.
- Several competitors hold patents on alternative core structures or different substitution patterns with overlapping therapeutic claims.
Geographic Patent Coverage:
- The patent's U.S. filing is part of a broader international family.
- Patent protections in Europe, Japan, and China are pending, with similar claims but modified language to accommodate local patent laws.
Patent Filing and Grant Timeline
| Event |
Date |
| Priority Date |
August 15, 2019 |
| PCT Application |
August 14, 2020 |
| U.S. Application Filed |
August 17, 2020 |
| Patent Grant |
February 7, 2023 |
Patentability Factors
- The claims demonstrate novelty based on unique substitution patterns not disclosed explicitly in prior art.
- Non-obviousness claims are supported by experimental data showing superior enzyme inhibition and pharmacokinetic properties over existing compounds.
- Utility is well-defined in the context of enzyme inhibition for specific disease indications.
Key Patent Limitations
- Limited to certain substitution patterns; compounds outside these configurations are not covered.
- Method claims are specific and do not encompass all synthetic routes for the core scaffold.
- The patent does not claim the broader class of pyrimidine derivatives or different enzyme targets.
Key Takeaways
- The patent provides a focused scope covering a specific set of substituted pyrimidine compounds designed for enzyme inhibition.
- Claims are moderately broad within a defined chemical space but exclude broader classes.
- The patent landscape features related compounds but distinguishes this invention on substitution specifics and pharmacological data.
- The patent's protection extends to therapeutic uses and synthesis methods, with a timeline indicating recent grant.
FAQs
1. Does the patent cover all pyrimidine compounds?
No, it covers specific substituted pyrimidine derivatives with defined substituents.
2. Can competitors develop similar compounds with different cores?
Yes, unless the core structure is also claimed elsewhere; these would fall outside the patent scope.
3. Are methods of synthesis protected?
Yes, specific synthetic routes are claimed, but they do not encompass all possible methods.
4. Does the patent prevent using the compounds for other diseases?
Claims specify certain therapeutic indications, but the compounds themselves could be used for other enzyme-inhibition purposes unless specifically excluded.
5. Is this patent likely to be challenged?
Potentially, given the existence of similar prior art, but its distinct substitution patterns and demonstrated utility strengthen its validity.
References
[1] U.S. Patent and Trademark Office. (2023). Patent 11,278,538.
[2] Prior art references and related patents obtained from USPTO public records.
